A new extended-release formulation of carbidopa/levodopa (CD/LD) appears to be as effective as standard CD/LD in stable patients with Parkinsons disease, according to the results of a small phase II study (Hinson et al. Clin Neuropharmacol 2009; 32: 189-192).